Oliver Hartley

Company: Orion Biotechnology

Job title: Vice President, Drug Discovery

Seminars:

Seizing the Value of Class B GPCRs to Develop Novel Drugs for Endocrine & Metabolic Indications 1:00 pm

With the recent successes of GLP-1 drugs such Ozempic and Wegovy, Class B GPCRs are gaining significant interest as they offer new opportunities to address a wide range of unmet patient needs, including endocrine and metabolic indications. Join this workshop for a deep-dive discussion into the structural and functional understanding of class B GPCRs as…Read more

day: Pre-Conference Workshop Day

Targeting Class B GPCRs to Advance the Next-Generation of Metabolic Therapeutics 8:30 am

Leveraging a novel drug modality and proprietary discovery platform to unlock Class B GPCRs Advancing a pipeline of differentiated therapeutics for obesity and metabolic disorders Capturing the untapped potential of Class B GPCRs with novel monotherapy and combination approachesRead more

day: Conference Day Two